Nanotechnology Declared a "Risky Little Business" by the Economist

A major feature story in this week's Economist magazine (November 24, 2007) highlights the enormous promise of nanotechnology-for breakthroughs in medicine, sustainable energy, and electronics. But the article, "A Little Risky Business," underscores the lack of research being done to determine how safe nanoscale materials are. And, despite nanotechnology's rapid commercialization, it highlights the lack of resources in government and industry that are being applied to address the problem. The story also considers the important question of whether current regulations are adequate to manage nanotechnology development safely.

The article is available at: http://www.economist.com/displaystory.cfm?story_id=10171212

Andrew Maynard, chief science advisor for the Wilson Center's Project on Emerging Nanotechnologies, is prominently featured in The Economist article. Maynard is a foremost expert on addressing possible nanotechnology risks and developing safe nanotechnologies. His Ph.D. is in ultrafine aerosol analysis from Cambridge University (UK). He is a frequent media guest and expert witness at Congressional hearings. He appears in the 2008 public television series, Nanotechnology: The Power of Small (see: www.fredfriendly.org).

Why: An exciting new field of research, nanotechnology is the ability to measure, see, manipulate and manufacture things usually between 1 and 100 nanometers. A nanometer is one billionth of a meter; a human hair is roughly 100,000 nanometers wide. Nanotechnology was incorporated into more than $50 billion in manufactured goods in 2006. By 2014, an estimated $2.6 trillion in manufactured goods worldwide will use nanotechnology, accounting for 15 percent of global output and 11 percent of manufacturing jobs.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.